1. Home
  2. TGE vs LUNG Comparison

TGE vs LUNG Comparison

Compare TGE & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TGE

The Generation Essentials Group Class A Ordinary Shares

HOLD

Current Price

$1.06

Market Cap

61.1M

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.26

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGE
LUNG
Founded
2023
1995
Country
France
United States
Employees
N/A
N/A
Industry
Newspapers/Magazines
Industrial Specialties
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.1M
57.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
TGE
LUNG
Price
$1.06
$1.26
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
28.8K
408.3K
Earning Date
04-29-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
$2.99
N/A
Revenue Growth
N/A
8.01
52 Week Low
$0.78
$1.13
52 Week High
$12.99
$3.88

Technical Indicators

Market Signals
Indicator
TGE
LUNG
Relative Strength Index (RSI) 42.54 43.06
Support Level $1.02 $1.13
Resistance Level $1.23 $1.64
Average True Range (ATR) 0.06 0.10
MACD 0.00 0.00
Stochastic Oscillator 11.67 19.05

Price Performance

Historical Comparison
TGE
LUNG

About TGE The Generation Essentials Group Class A Ordinary Shares

The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: